Understanding P-gp and BCRP Inhibition Assay Design and Outcomes

Описание: Originally Aired: 12/11/2018 8:00:00 AM
Presenter: Andrea Wolff, XenoTech Director of Services Logistics

Synopsis:
In vitro drug transporter inhibition studies are recognized for their importance due to the major role transporters play in absorption, distribution and excretion of compounds, and the toxicological and pharmacological consequences of transporter-mediated drug-drug interactions (DDI). P-gp and BCRP transporters limit intestinal absorption and blood-brain barrier penetration, and facilitate excretion into bile and urine.

Andrea Wolff, XenoTech Director of Services Logistics, recently provided a webinar to the SimCyp transporter discussion group on P-gp and BCRP Inhibition. For those who did not have the opportunity to hear her presentation, we are hosted a follow-up webinar on Dec. 11th.

Key concepts discussed in this webinar will include:
Description of the in vitro test systems used to evaluate P-gp and - BCRP inhibition at XenoTech and the advantages/disadvantages of these assays
Description of the test system qualification process that takes places prior to offering these assays in definitive studies
Comparison of IC50 values obtained from the different test systems
Comparison of IC50 and Ki values determined with the vesicle test system
How IC50 and Ki values are used to evaluate clinical relevance

Download a copy of the slides: https://www.xenotech.com/access-adme-...
Questions, comments and requests: https://www.xenotech.com/contact-us
More information on our transporter services: https://www.xenotech.com/services/dru...
Other previously aired webinars: https://www.xenotech.com/scientific-r...
Upcoming webinars: https://www.xenotech.com/scientific-r...

About the presenter: Andrea Wolff received her Bachelors of Science with a double major in Chemistry and Biology at Baker University and she joined the XenoTech team in 1999. She has more than 20 years of experience with GLP and non-GLP in vitro metabolism and transporter studies at XenoTech. Her experience started as an analyst and then Study Director focusing on in vitro drug metabolism studies. After over 10 years focusing on in vitro metabolism, her focus shifted to in vitro drug transporter studies, serving as a Study Director and then Manager for 5 years. She then expanded her focus, managing drug interaction studies across multiple disciplines (in vitro drug metabolism, drug transporters, enzyme induction and enzyme inhibition) and providing guidance to clients on the regulatory requirements for performing in vitro drug interaction studies. Andrea is now serving as the Director of Service Logistics at XenoTech, managing several core service support teams that cover protocol writing, report writing, data processing and project management. She is responsible for the quality and timelines associated with all contract study deliverables executed at XenoTech.